Skip to main content
Top
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Research article

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer

Authors: Satoru Taguchi, Hiroshi Fukuhara, Takeshi Azuma, Motofumi Suzuki, Tetsuya Fujimura, Tohru Nakagawa, Akira Ishikawa, Haruki Kume, Yasuhiko Igawa, Yukio Homma

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

The optimal timing of salvage androgen deprivation therapy (ADT) for biochemical recurrence after radical prostatectomy is controversial. We compared the outcomes of ultra-early versus early salvage ADT.

Methods

Among 855 patients undergoing radical prostatectomy at our institution between 2000 and 2012, we identified 121 with adjuvant-treatment-naïve pT2-4N0M0 prostate cancer who received salvage ADT for biochemical recurrence. These patients were divided into an ultra-early salvage ADT group (n = 51), who started salvage ADT before meeting the standardized definition of biochemical recurrence in Japan (two consecutive prostate-specific antigen [PSA] values ≥0.2 ng/ml), and an early salvage ADT group (n = 70) who started salvage ADT when they met the definition. The ultra-early ADT group consisted of those who started salvage ADT with a single PSA value ≥0.2 ng/ml (n = 30) or with two consecutive PSA values >0.1 ng/ml and rising (n = 21). The primary endpoint was biochemical recurrence after salvage ADT, defined as a single PSA value ≥0.2 ng/ml after PSA nadir following salvage ADT. Secondary endpoints were clinical metastasis and cancer-specific survival. A Cox proportional hazards model was used for multivariate analysis. The median follow-up was 65.5 months.

Results

Biochemical recurrence occurred in one patient (2.0%) in the ultra-early group and in 12 (17.1%) in the early salvage ADT group. Multivariate analysis identified ultra-early salvage ADT and preoperative Gleason score ≤7 as independent negative predictors of biochemical recurrence after salvage ADT. Only one patient in the early salvage ADT group developed clinical metastasis to a left supraclavicular lymph node, and no patient died from prostate cancer during follow-up. The major limitations of this study were its retrospective design, selection bias, and the possibility that the ultra-early salvage ADT group may have included patients without biochemical recurrence.

Conclusions

Ultra-early salvage ADT was an independent negative predictor of biochemical recurrence after salvage ADT in post-prostatectomy patients. Further consideration should be given to the use of salvage ADT before meeting the current definition of biochemical recurrence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002, 167: 528-534. 10.1016/S0022-5347(01)69079-7.CrossRefPubMed Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002, 167: 528-534. 10.1016/S0022-5347(01)69079-7.CrossRefPubMed
2.
go back to reference Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retro-pubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004, 172: 910-914. 10.1097/01.ju.0000134888.22332.bb.CrossRefPubMed Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retro-pubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004, 172: 910-914. 10.1097/01.ju.0000134888.22332.bb.CrossRefPubMed
3.
go back to reference Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ: Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013, 64: 905-915. 10.1016/j.eururo.2013.05.025.CrossRefPubMed Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ: Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013, 64: 905-915. 10.1016/j.eururo.2013.05.025.CrossRefPubMed
4.
go back to reference Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008, 179: 1830-1837. 10.1016/j.juro.2008.01.022.CrossRefPubMed Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008, 179: 1830-1837. 10.1016/j.juro.2008.01.022.CrossRefPubMed
5.
go back to reference Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004, 171: 1141-1147. 10.1097/01.ju.0000113794.34810.d0.CrossRefPubMed Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004, 171: 1141-1147. 10.1097/01.ju.0000113794.34810.d0.CrossRefPubMed
6.
go back to reference Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ: Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo. 2013.08.022 DOI:10.1016/j.eururo.%202013.08.022 Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ: Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. In press. http://​dx.​doi.​org/​10.​1016/​j.​eururo. 2013.08.022 DOI:10.1016/j.eururo.%202013.08.022
7.
go back to reference Hirao Y: Clinical Practice Guidelines for Prostate Cancer: The Japanese Urological Association 2012 update. 2012, Tokyo: Kanehara-shuppan Press, (in Japanese) Hirao Y: Clinical Practice Guidelines for Prostate Cancer: The Japanese Urological Association 2012 update. 2012, Tokyo: Kanehara-shuppan Press, (in Japanese)
8.
go back to reference The Japanese Urological Association, the Japanese Society of Pathology and Japan Radiological Society: General Rule for Clinical and Pathological Studies on Prostate Cancer, the fourth edition. 2010, Tokyo: Kanehara and Co., Ltd, (in Japanese) The Japanese Urological Association, the Japanese Society of Pathology and Japan Radiological Society: General Rule for Clinical and Pathological Studies on Prostate Cancer, the fourth edition. 2010, Tokyo: Kanehara and Co., Ltd, (in Japanese)
9.
go back to reference Ryan CJ, Small EJ: Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005, 23: 8225-8231. 10.1200/JCO.2005.03.5311.CrossRefPubMed Ryan CJ, Small EJ: Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005, 23: 8225-8231. 10.1200/JCO.2005.03.5311.CrossRefPubMed
10.
go back to reference Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, Di'SantAgnese PA, Trump D, Eastern Cooperative Oncology Group study EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006, 7: 472-479. 10.1016/S1470-2045(06)70700-8.CrossRefPubMed Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, Di'SantAgnese PA, Trump D, Eastern Cooperative Oncology Group study EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006, 7: 472-479. 10.1016/S1470-2045(06)70700-8.CrossRefPubMed
11.
go back to reference Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999, 341: 1781-88. 10.1056/NEJM199912093412401.CrossRefPubMed Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999, 341: 1781-88. 10.1056/NEJM199912093412401.CrossRefPubMed
13.
go back to reference Sato YT, Fukuhara H, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M, Homma Y: Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 2014, 14: 13-10.1186/1471-2490-14-13.CrossRefPubMedCentral Sato YT, Fukuhara H, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M, Homma Y: Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 2014, 14: 13-10.1186/1471-2490-14-13.CrossRefPubMedCentral
14.
go back to reference Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L: Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of the EORTC 30846—a phase III study. J Urol. 2004, 272: 923-927.CrossRef Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L: Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of the EORTC 30846—a phase III study. J Urol. 2004, 272: 923-927.CrossRef
15.
go back to reference Messing EM: A structured debate: immediate vs deferred androgen suppression in prostate cancer—evidence for deferred treatment (editorial). J Urol. 2001, 166: 515-16.CrossRef Messing EM: A structured debate: immediate vs deferred androgen suppression in prostate cancer—evidence for deferred treatment (editorial). J Urol. 2001, 166: 515-16.CrossRef
16.
go back to reference Isaacs JT: Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res. 1989, 49: 6290-6294.PubMed Isaacs JT: Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res. 1989, 49: 6290-6294.PubMed
17.
go back to reference Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG: Early castration reduces prostatic carcinogenesis in transgenic mice. Urology. 1999, 54: 1112-1119. 10.1016/S0090-4295(99)00297-6.CrossRefPubMed Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG: Early castration reduces prostatic carcinogenesis in transgenic mice. Urology. 1999, 54: 1112-1119. 10.1016/S0090-4295(99)00297-6.CrossRefPubMed
18.
go back to reference Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59: 5030-5036.PubMed Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59: 5030-5036.PubMed
19.
go back to reference Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H: Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012, 62: 472-487. 10.1016/j.eururo.2012.04.056.CrossRefPubMed Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H: Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012, 62: 472-487. 10.1016/j.eururo.2012.04.056.CrossRefPubMed
Metadata
Title
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
Authors
Satoru Taguchi
Hiroshi Fukuhara
Takeshi Azuma
Motofumi Suzuki
Tetsuya Fujimura
Tohru Nakagawa
Akira Ishikawa
Haruki Kume
Yasuhiko Igawa
Yukio Homma
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-81

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue